radiopharmaceuticalITM gets equity to launch Phase III lead radiopharmaceutical ITM-11ITM Isotope Technologies Munich SE has raised €188m ito boost radiopharma pipeline, contract manufacturing cpacity, and launch ITM-11. more ➔
CollaborationQuantro Therapeutics cashes in milestone payment from Boehringer IngelheimViennese biotech QUANTRO Therapeutics identifies small molecule targeting an onkogenic transcription factor in Boehringer Ingelheim collab. more ➔
cell cultureDefiniGEN and Atelerix prevent freezing damage in cell modelsDefiniGEN Ltd., and Atelerix Ltd. have successfully shipped in vitro liver models from the UK to the US without freezing them thus preventing cell damage and loss-of function. more ➔
CDMOWacker Chemie AG opens €100m RNA manufacturing siteWith the opening of a production centRE for RNA vaccines and therapeutics, German CDMO Wacker Biotech is expanding its expertise in the field of RNA active ingredients. more ➔
CROConsortium led by Evotec enters obesity drug spaceDrug discovery CRO Evotec SE announced has entered into a partnership with Inserm, Lille University Hospital and Inserm Transfert to screen new biomarkers and targets in obesity and metabolic diseas … more ➔
Lab automationSemarion Ltd. wins Ignite SME award at SLAS EuropeUK-based Semarion Ltd. was honoured as the most innovative company in the field of laboratory automation at SLAS Europe 2024 in Barcelona. more ➔
acquisitionMSD grabs Eyebiotech Ltd for US$1.3bn upfrontUS pharma giant Merck Sharp & Dohme (MSD) is decided to acquire London-based ophtalmology expert Eyebiotech Ltd for upt to US$3bn., US$1.7bn in future milestones. more ➔
SLASLab automationSLAS Europe 2024 honours products with most impactSwiss Seed Biosciences SA and UK-based Cryologyx Ltd have won the SLAS Europe Product Award 2024 for product developments with transformational potential for the sector. more ➔
VirologyHornet Therapeutics reports first data of EBV-triggered disease blocker Hornet Therapeutics Ltd will use a US$5m seed financing to launch clinical tests of its IDO1 blocker HTX-201within the next 12 to 18 months to target post-transplant lymphoproliferative disease. more ➔
AstraZeneca puts step into obesity marketSwiss obesity start up SixPeaks Bio AG has made a good start, announcing a US$30m Series A financing led by Versant Ventures and a US$80m biobucks partnership with AstraZeneca plc. more ➔
SLAS
